Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
The Journal of Biological Chemistry|March 6, 2025
Binding mode between peptidyl-tRNA hydrolase and the peptidyl-A76 moiety of the substrateYuji Uehara, Ami Matsumoto, Tomonori Nakazawa, et al.
Translational Lung Cancer Research|March 14, 2022
Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapyYuji Uehara, Taiki Hakozaki, Rui Kitadai, et al.
European Journal of Haematology|February 17, 2015
Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutationMasato Kobayashi, Shiori Kuroki, Yu Tanaka, et al.
JAMA Network Open|September 15, 2023
Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center HospitalYuji Uehara, Takafumi Koyama, Yuki Katsuya, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 5, 2026
Targeting MET in EGFR-mutated NSCLCStephanie P L Saw, Molly S C Li, Sehhoon Park, et al.
Cancer Immunology, Immunotherapy : CII|November 3, 2025
CD40 transcriptomic expression patterns across malignancies: implications for clinical trials of CD40 agonistsYuji Uehara, Daisuke Nishizaki, Yu Fujiwara, et al.
Cancer Research and Treatment|December 19, 2025
Utilization, Reimbursement, and Barriers to Accessing Sequencing Tests for Cancer Care in the Asia-Pacific Region: KSMO Initiatives to Address Cancer Care InequityOmali Pitiyarachchi, Aaron C Tan, Tawasapon Thambamroong, et al.
Clinical Lung Cancer|May 22, 2026
Predicting Radiation-Induced Esophagitis in Locally Advanced NSCLC Using Baseline Clinical Factors: A Model From the Japan Lung Cancer Society Integrated Phase II-III DatabaseYuji Uehara, Kageaki Watanabe, Jun Tamura, et al.
JTO Clinical and Research Reports|February 26, 2025
Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung AdenocarcinomaYuji Uehara, Hiroki Izumi, Tetsuro Taki, et al.
Journal for Immunotherapy of Cancer|December 8, 2025
PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLCJun Miyakoshi, Tatsuya Yoshida, Yuji Uehara, et al.
Pageof 3